Oral JAK Inhibitor Promising in Ankylosing Spondylitis

A sizeable proportion of patients were also taking a disease-modifying antirheumatic drug at study entry.

The primary efficacy end point was ASAS20, defined as an improvement of at least 20% in response criteria, at week 12.

“The predicted dose of 5 mg twice daily had a response rate of 63%, which was almost 23% higher than the response rate in placebo controls,” Dr van der Heijde reported. The 10 mg twice-daily dose “had a high response rate as well.”

In fact, the ASAS20 response rate was 15.8% higher in the 2 mg group than in the placebo group, 22.9% higher in the 5 mg group, and 27.3% higher in the 10 mg group.

Table. Response Rates at 16 Weeks

Criteria Tofacitinib 2 mg Group Tofacitinib 5 mg Group Tofacitinib 10 mg Group Placebo Group
ASAS20 56.0% 63.0% 67.4% 40.1%
BASDAI50 46.2% 42.3% 42.3% 23.5%

Next Page

Be the first to comment

Leave a Reply

Your email address will not be published.